These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 24852682

  • 21. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [Abstract] [Full Text] [Related]

  • 22. Longitudinal brain structural changes in preclinical Alzheimer's disease.
    Pegueroles J, Vilaplana E, Montal V, Sampedro F, Alcolea D, Carmona-Iragui M, Clarimon J, Blesa R, Lleó A, Fortea J, Alzheimer's Disease Neuroimaging Initiative.
    Alzheimers Dement; 2017 May; 13(5):499-509. PubMed ID: 27693189
    [Abstract] [Full Text] [Related]

  • 23. Idiopathic normal-pressure hydrocephalus, cerebrospinal fluid biomarkers, and the cerebrospinal fluid tap test.
    Kang K, Ko PW, Jin M, Suk K, Lee HW.
    J Clin Neurosci; 2014 Aug; 21(8):1398-403. PubMed ID: 24836892
    [Abstract] [Full Text] [Related]

  • 24. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting.
    Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, Laplanche JL, Peoc'h K, Schraen S, Pasquier F, Touchon J, Hugon J, Lehmann S, Gabelle A.
    Alzheimers Dement; 2013 Jul; 9(4):406-13. PubMed ID: 23141384
    [Abstract] [Full Text] [Related]

  • 25. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2016 Jul; 51(4):1085-97. PubMed ID: 26967213
    [Abstract] [Full Text] [Related]

  • 26. CSF tau levels influence cortical plasticity in Alzheimer's disease patients.
    Koch G, Esposito Z, Kusayanagi H, Monteleone F, Codecá C, Di Lorenzo F, Caltagirone C, Bernardi G, Martorana A.
    J Alzheimers Dis; 2011 Jul; 26(1):181-6. PubMed ID: 21606570
    [Abstract] [Full Text] [Related]

  • 27. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [Abstract] [Full Text] [Related]

  • 28. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chen J, Fang Y, He H, Ning Y.
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [Abstract] [Full Text] [Related]

  • 29. Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.
    Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D.
    J Alzheimers Dis; 2013 May; 33(3):775-80. PubMed ID: 22986776
    [Abstract] [Full Text] [Related]

  • 30. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, Sánchez-Valle R, Molinuevo JL.
    J Alzheimers Dis; 2011 May; 23(2):319-26. PubMed ID: 21098971
    [Abstract] [Full Text] [Related]

  • 31. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 May; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 32. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202 Investigators.
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [Abstract] [Full Text] [Related]

  • 33. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
    Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G.
    J Alzheimers Dis; 2012 Aug; 31(4):865-78. PubMed ID: 22717612
    [Abstract] [Full Text] [Related]

  • 34. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease.
    Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S.
    J Alzheimers Dis; 2013 Aug; 33(3):807-22. PubMed ID: 23034521
    [Abstract] [Full Text] [Related]

  • 35. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C, Soldan A, Sloane K, Cai Q, Wang J, Wang MC, Moghekar A, Miller MI, Albert M, BIOCARD Research Team.
    Neuroimage Clin; 2017 Aug; 16():439-446. PubMed ID: 28879085
    [Abstract] [Full Text] [Related]

  • 36. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.
    J Alzheimers Dis; 2011 Aug; 24(3):537-46. PubMed ID: 21297262
    [Abstract] [Full Text] [Related]

  • 37. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [Abstract] [Full Text] [Related]

  • 38. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.
    Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.
    Alzheimers Dement; 2012 Nov; 8(6):520-7. PubMed ID: 22677492
    [Abstract] [Full Text] [Related]

  • 39. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M.
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [Abstract] [Full Text] [Related]

  • 40. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.